RT Journal Article
SR Electronic
T1 National interest may require distributing COVID-19 vaccines to other countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.11.21249610
DO 10.1101/2021.01.11.21249610
A1 Rotesi, Tiziano
A1 Pin, Paolo
A1 Cucciniello, Maria
A1 Malik, Amyn A.
A1 Paintsil, Elliott E.
A1 Bokemper, Scott E.
A1 Willebrand, Kathryn
A1 Huber, Gregory A.
A1 Melegaro, Alessia
A1 Omer, Saad B.
YR 2021
UL http://medrxiv.org/content/early/2021/01/14/2021.01.11.21249610.abstract
AB As the clinical trials for COVID-19 vaccine progress, understanding how to distribute the initially scarce doses is of paramount importance and a quantitative analysis of the trade-offs involved in domestic-only versus cooperative distribution is still missing. In this study we use a network Susceptible-Infected-Removed (SIR) model to show under which circumstances it is in a country’s self-interest to ensure other countries can also obtain a COVID-19 vaccine rather than focusing only on vaccination of their own residents. In particular, we focus our analysis on the US’s decision and estimate the internal burden of COVID-19 disease under different scenarios about vaccine cooperation. We show that in scenarios in which the US has reached the threshold for domestic herd immunity, the US may find it optimal to donate doses to other countries with lower vaccination coverage, as this would allow for a sharp reduction in the inflow of infected individuals from abroad.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPP and AM acknowledges support from the Italian Ministry of Education Progetti di Rilevante Interesse Nazionale (PRIN), respectively grant number 2017ELHNNJ and 20177BRJXS. AAM., EL, KW, SO acknowledge support from the Yale Institute for Global Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human subjects data was used or produced during this research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData downloaded from International Civil Aviation Organization cannot be shared, but can be purchased from the provider. https://doi.org/10.5281/zenodo.4432995